Avalon GloboCare Corp. is a Delaware-incorporated company focused on developing precision diagnostic consumer products, notably the Keto Air breathalyzer, and has diversified into laboratory services and real estate ownership, with recent financial challenges and ongoing strategic initiatives.

# Company Summary

## Overview
- **Company Name:** Avalon GloboCare Corp.
- **Incorporation:** Delaware
- **Primary Business Focus:** Developing and delivering precision diagnostic consumer products.

## Main Operations
- **Current Product:** 
  - **Keto Air:** A handheld breathalyzer device that tests ketosis levels in exhaled breath.
  - **Technology:** Uses the concentration of acetone in breath (ppm) to determine ketosis status:
    - Inadequate ketosis: 0–3.99 ppm
    - Mild ketosis: 4–9.99 ppm
    - Optimal ketosis: 10–40 ppm
    - Alarming level: >40 ppm
  - **Regulatory Status:** Registered with the FDA as a Class I medical device.
  - **Software Integration:** Paired with an "AI Nutritionist" app that connects via Bluetooth, available on Google Play and under review by the Apple App Store.
  - **Market Target:** Diabetes and obesity markets, with sales conducted through the KetoAir website and social media.

- **Laboratory Services:** 
  - Provided broad diagnostic tests (including drug testing, toxicology, general bloodwork, anatomic pathology) in 2023 and 2024.
  - **Ownership Interest:** Held a 40% membership in Laboratory Services MSO, LLC.
  - **Discontinuation:** As of February 2025, the company redeemed its investment and no longer offers laboratory services.

- **Real Estate Ownership:**
  - Owns a commercial property at **4400 Route 9 South, Freehold, New Jersey**.
  - The property functions as the company's headquarters and operates with several tenants generating rental income.

## Employees
- As of March 31, 2025: **5 employees** (4 full-time, none in unions).

## Revenue and Income
- **2024 Revenue:**
  - Real property rental: **$1,333,403** (6.2% increase from 2023)
  - Laboratory services: Discontinued in February 2025
- **2024 Net Loss:**
  - **$7,903,394** (improved from previous losses)
- **2023 Net Loss:** 
  - **$16,707,010**
- **Income Details:**
  - No income taxes paid for 2023 and 2024 due to losses.
  - Loss attributable to common shareholders in 2024: **$7,903,394**

## Business Strategy and Development
- Focused on product commercialization of KetoAir.
- Suspended R&D related to cellular therapy to prioritize core product and business strategies.
- Engaged in strategic development initiatives, including a planned merger with YOOV.
- Actively pursuing intellectual property protection via joint patent filings with MIT.

## Key Financials
- **Cash balance (March 31, 2025):** Approximately **$2.86 million**.
- **Total liabilities (2024):** Approximately **$13.88 million**.
- **Working capital deficit (2024):** Approximately **$10.65 million**.
- **Employees:** 5 (as of March 2025).

## Market Presence
- Trades on **NASDAQ Capital Market** under symbol **ALBT**.
- Stock price as of March 28, 2025: **$5.27**.
- Number of stockholders of record (March 2025): approximately **237**.

## Regulatory and Legal
- Compliant with FDA regulations for KetoAir; pursuing approvals for additional products.
- Discontinued Chinese operations in late 2022.
- Engaged in legal proceedings related to prior assets, with ongoing litigation for trade secret claims.

This summary reflects the company's primary business activities, product offerings, financial status, corporate structure, and strategic initiatives based solely on the provided document.

The company specializes in innovative precision diagnostics and clinical laboratory services, focusing on laboratory acquisitions, R&D collaborations, and product commercialization.

# Company Overview

## Business Operations
The company is dedicated to developing and delivering innovative, transformative precision diagnostics and clinical laboratory services. Its primary strategy involves acquiring ownership or license rights for precision diagnostic assets, genetic testing, and clinical laboratory services through joint ventures, share ownership structures, or distribution rights.

## Key Areas of Focus
1. **Laboratory Acquisitions:**
   - The company has initiated a laboratory rollup strategy, acquiring laboratories that align with its commercial strategy.
   - On February 9, 2023, it completed the acquisition of 40% of Lab Services MSO, a laboratory focused on toxicology and wellness testing.
   - Lab Services MSO provides a broad portfolio of diagnostic tests, including drug testing, genetic testing, and various chemistry tests.

2. **Research and Development:**
   - The company collaborates with the Massachusetts Institute of Technology (MIT) to bring forward intellectual property via joint patent filings and research projects.
   - It is currently focusing on the commercialization of genetically-based testing and breathalyzer technology for monitoring ketosis.

3. **Product Commercialization:**
   - The company has exclusive rights to distribute the KetoAir breathalyzer system, a device for detecting acetone levels in exhaled breath, targeting the diabetes and obesity markets.

4. **Sales and Marketing:**
   - Plans are underway to expand operations through strategic relationships and acquisitions in the laboratory and diagnostic testing sectors.
   - The company plans to launch sales of KetoAir in the U.S. and has engaged a marketing expert for promotion.

## Financials
- The company's operations have resulted in **net losses** of approximately **$16.7 million** and **$11.9 million** for the years ending December 31, 2023, and 2022, respectively. 
- An **accumulated deficit** stood at approximately **$79.8 million** as of December 31, 2023.
- The company had cash reserves of approximately **$285,000** as of December 31, 2023, indicating a need for additional capital to support continued operations.

## Employment
- As of March 29, 2024, the company employed **five employees**, four of whom are full-time.

## Customer Base
- The specifics regarding the number of customers are not detailed in the provided text, but the company aims to serve various stakeholders, including practitioners, healthcare providers, Managed Care Organizations (MCOs), and patients through its laboratory services and products.

---

## Conclusion
The company is positioned to contribute significantly to the precision diagnostics market by leveraging its laboratory acquisitions, R&D collaborations, and innovative product offerings, while aiming to achieve profitability in the face of financial challenges and competitive pressures.

Avalon GloboCare Corp.

10-K / March 31, 2025

10-K / April 15, 2024

10-K / March 31, 2025

Company Summary

Overview

Main Operations

Employees

Revenue and Income

Business Strategy and Development

Key Financials

Market Presence

Regulatory and Legal